Dagens Industri SV

Novo Nordisk och Hims återförenas – aktien rusar i efterhandeln

Novo Nordisk uppges återuppta samarbetet med e-hälsobolaget Hims & Hers – bara månader efter en uppmärksammad rättstrid om kopior på bantningssuccén Wegovy. Uppgifterna fick Hims aktie att rusa 40 procent i efterhandeln i New York.

Mar 07, 2026 &03140707202631; 09:14 UTC www.di.se Trending 2/5

Read original on www.di.se ↗

↗

Positive for markets

Sentiment score: +75/100

High impact Immediate effect (hours)

WHAT THIS MEANS

Novo Nordisk and Hims & Hers are reportedly resuming their partnership after a high-profile legal dispute over Wegovy copies, causing Hims stock to surge 40% in after-hours trading. This reconciliation signals renewed commercial collaboration in the lucrative GLP-1 weight loss medication market.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

HIMS

HIMSStock

Expected to rise

Partnership resumption with Novo Nordisk eliminates legal uncertainty and restores revenue-generating collaboration in GLP-1 market

↑

Novo Nordisk

NVOStock

Expected to rise

Expanded distribution channel through Hims platform strengthens Wegovy market penetration and revenue potential

↑

S&P 500

^GSPCIndex

Expected to rise

Positive sentiment in healthcare/biotech sector from resolved litigation and partnership expansion

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Long Hims on partnership confirmation and sustained GLP-1 demand; monitor Novo Nordisk for guidance updates on expanded distribution. Consider healthcare sector rotation given positive resolution of litigation overhang.

KEY SIGNALS

Legal dispute resolution removes downside riskPartnership resumption validates Hims business modelGLP-1 market expansion continues with renewed distribution40% after-hours surge indicates strong investor confidenceNovo Nordisk validates e-health distribution strategy

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticalsDigital Health

Analysis generated on Mar 09, 2026 at 18:08 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Dagens Industri. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Novo Nordisk och Hims återförenas – aktien rusar i efterhandeln

RELATED INTELLIGENCE